Allogene Therapeutics (NASDAQ:ALLO) Posts Earnings Results, Beats Expectations By $0.06 EPS

Allogene Therapeutics (NASDAQ:ALLO) announced its quarterly earnings data on Thursday. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06, Zacks reports.

Allogene Therapeutics Stock Performance

Shares of Allogene Therapeutics stock opened at $1.94 on Friday. Allogene Therapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $4.89. The firm has a 50-day simple moving average of $1.94 and a two-hundred day simple moving average of $2.32. The company has a market cap of $406.76 million, a P/E ratio of -1.24 and a beta of 1.02.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ALLO shares. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $14.00 price target on shares of Allogene Therapeutics in a report on Friday. Citizens Jmp raised shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a report on Friday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price target on shares of Allogene Therapeutics in a report on Friday. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $9.40.

Insider Buying and Selling

In related news, EVP Zachary Roberts sold 27,199 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total transaction of $48,414.22. Following the completion of the transaction, the executive vice president now owns 488,054 shares in the company, valued at $868,736.12. This represents a 5.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Timothy L. Moore sold 14,746 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $1.71, for a total transaction of $25,215.66. Following the transaction, the insider now owns 250,713 shares of the company’s stock, valued at approximately $428,719.23. This trade represents a 5.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 52,710 shares of company stock worth $92,125 in the last 90 days. Insiders own 24.30% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).